- Previous Close
6.60 - Open
6.64 - Bid 4.90 x 200
- Ask 8.47 x 200
- Day's Range
6.51 - 6.95 - 52 Week Range
3.68 - 7.99 - Volume
189,913 - Avg. Volume
211,771 - Market Cap (intraday)
252.883M - Beta (5Y Monthly) 0.97
- PE Ratio (TTM)
-- - EPS (TTM)
-0.56 - Earnings Date Apr 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
www.lifecore.com524
Full Time Employees
May 26
Fiscal Year Ends
Sector
Recent News: LFCR
View More
Performance Overview: LFCR
Trailing total returns as of 3/27/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LFCR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LFCR
View MoreValuation Measures
Market Cap
252.88M
Enterprise Value
374.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.81
Price/Book (mrq)
16.37
Enterprise Value/Revenue
2.86
Enterprise Value/EBITDA
25.07
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.89%
Return on Assets (ttm)
-2.47%
Return on Equity (ttm)
-29.58%
Revenue (ttm)
130.86M
Net Income Avi to Common (ttm)
-17.23M
Diluted EPS (ttm)
-0.56
Balance Sheet and Cash Flow
Total Cash (mrq)
9.46M
Total Debt/Equity (mrq)
219.78%
Levered Free Cash Flow (ttm)
-22.68M
Research Analysis: LFCR
View MoreResearch Reports: LFCR
View MoreDaily – Vickers Top Buyers & Sellers for 01/09/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/18/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 07/14/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 07/13/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.